Furthermore, to evaluate the impact of PD-1 blockade on different subtypes of SFTSV replication, PBMCs from healthy individuals were treated with NbP45 or Tislelizumab, followed by infection with SFTSV (subtypes D and B) at an MOI of 1. Here, PDCD1 is linked to infection.